Platinum Penny

[JoeyClams]

CVSS NEWS!!!

CVSS -- Cardiovascular Sciences, Inc. Completing Initial Research in Development of Antiadhesion Material (Press Release)

Orlando, FL, Mar 19, 2007 (Pink Sheets News Service) — Cardiovascular Sciences, Inc. of Orlando, FL (CVSS) has completed its first year of funded research at the University of Central Florida. Adhesive scar tissue forms as a result of any surgical procedure and often creates pain and other complications for patients. The adhesions can impair healing, restrict movement, cause intestinal obstruction and make further surgical procedures difficult or unfeasible.
Cardiovascular Sciences research is targeted at developing a material that can be applied internally during surgery to almost completely prevent the formation of any adhesive tissue. Current product development has generated a post-surgical antiadhesion material that has surpassed expectations, both in terms of time for development and in the physical characteristics of the material.

The Company's sponsored research with the Chemistry Department at UCF, led by the Department Chairman, Dr. Kevin Belfield, PhD, has provided results beyond Cardiovascular Sciences plans and projections. The company now has several prototypes of their proprietary anti-adhesion material and the technology by which to manipulate its properties. The company is now ready to move ahead with expanded animal studies to further investigate the safety and efficacy of the product. The next stage of research has already been outlined, examining material modifications which promise the leading edge advantage in this field.

Once the expanded animal trials are initiated and operational financing is assured, the Company expects their first product to be market-ready 18 to 24 months later. The company is now in negotiations with several interested parties with regard to the financing required to bring the product to market and beyond. The initial target market is in the veterinary field with a market potential for anti-adhesion applications of $250 million in the United States alone. Applications and products for the human market will be addressed as successful entry into the veterinary arena is developed, revenue from which will help fund product development and the entry into the market for use in people.
N
ot incidental to these very positive developments has been the extensive assistance and resources provided by the award winning University of Central Florida High Tech Incubator program. Cardiovascular Sciences, Inc. is just passing the first anniversary of its participation in the program and the company?s operations in the incubator facilities at the UCF Research Park. Dr. Larry Hooper, the company?s CEO, expressed, ?The Incubator [UCF] is the principle factor that has allowed us to progress this far and at this rate. Our participation in the program removes a lot of the usual worries and stress so that we can more fully concentrate on those issues and problems specific to our field of endeavor.
About Cardiovascular Sciences, Inc.

Based in Orlando, Florida, Cardiovascular Sciences Inc. is a technology company focused on the development of innovative medical products. Cardiovascular Sciences is currently developing proprietary technology for the prevention of post-surgical adhesions. Adhesions are fibrous scar tissue formations that develop between tissues or organs following trauma, or the ?insult? to tissues and organs associated with virtually any surgical procedure. The currently available techniques, methods, and products used in treatment of these applications are usually no more than 50% effective. Cardiovascular Sciences? novel anti-adhesion products are being developed to be more effective, easier to handle, and much less costly than those currently on the market.